R59- HZNP
Re, just asking. Not saying I want to sell here, but surely frustrated. I will point out though that Mizuho bringing their target down 55% does lower the average analyst lowering after no Frederich Ataxia more than 10%. I mean I don't think you figured Mizuho in the mix. Even so, very hard for me to sell here, as analysts still feel $2.45 non gaap for 2017, which would be 25% EPS growth over 2016. I do think the sector stinks though, and may be in the dumper for some time if Trump really is tougher on the sector than Hillary would have been, like he says. Of course time will tell on that. In the meantime, yes, HZNP at $15 or under looks like a great risk/reward